CiVi 030
Severe Frostbite
Phase 3Active (AURORA trial)
Key Facts
About CiVi Biopharma
CiVi Biopharma Holding Corp. is a clinical-stage R&D biotech founded in 2017 with a mission to create novel cardiovascular and metabolic therapies. The company leverages antisense oligonucleotide technology, with a pipeline featuring an intravenous therapy for severe frostbite (in Phase 3) and a next-generation oral PCSK9 inhibitor in pre-clinical development. Led by an experienced team with deep cardiovascular and RNA therapeutics expertise, CiVi aims to address significant unmet needs in lipid management and orphan diseases.
View full company profile